Brief: Sana Biotechnology And Mayo Clinic Announce Strategic Collaboration Focused On Improving Care In Type 1 Diabetes And Accelerating Development Of Sc451
13/04/2026 21:55
April 13 (Reuters) - Sana Biotechnology Inc SANA.O: SANA BIOTECHNOLOGY AND MAYO CLINIC ANNOUNCE STRATEGIC COLLABORATION FOCUSED ON IMPROVING CARE IN TYPE 1 DIABETES AND ACCELERATING DEVELOPMENT OF SC451 Source text: ID:nGNX85jsRW Further company coverage: SANA.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Sana Biotechnology
See all newsSana Biotechnology Inc reports results for the quarter ended June 30 - Earnings Summary
Sana Biotechnology Q2 adjusted loss narrows, beats estimates
Brief: Sana Biotechnology Q2 Adjusted EPS USD -0.13 Vs. IBES Estimate USD -0.15
Sana Biotechnology posts Q1 adjusted loss narrower than expected, extends cash runway
Brief: Sana Biotechnology Q1 Adjusted EPS USD -0.14 Vs. IBES Estimate USD -0.17